249 related articles for article (PubMed ID: 18248270)
1. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
Hanefeld M; Schaper F
Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
4. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
5. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
[TBL] [Abstract][Full Text] [Related]
6. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.
Hanefeld M; Schaper F; Koehler C
Cardiovasc Drugs Ther; 2008 Jun; 22(3):225-31. PubMed ID: 18309462
[TBL] [Abstract][Full Text] [Related]
7. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
Delorme S; Chiasson JL
Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
[TBL] [Abstract][Full Text] [Related]
8. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
9. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
Chiasson JL
Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
[TBL] [Abstract][Full Text] [Related]
10. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.
Pan CY; Landen H
Clin Drug Investig; 2007; 27(6):397-405. PubMed ID: 17506590
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
13. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
14. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
[TBL] [Abstract][Full Text] [Related]
15. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
Nishimura R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
[No Abstract] [Full Text] [Related]
16. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
17. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
19. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]